Exploring the predictive "psycho-biomarkers" for checkpoint immunotherapy in cancer.

ABSTRACT:

Background

In recent decades, cancer immunotherapy has transformed the treatment landscape, offering significant advantages over traditional therapies by improving progression-free survival (PFS) and overall survival (OS). However, immune checkpoint inhibitors (ICIs) treatment has been associated with an increased risk of mortality in its early stages. Therefore, identifying reliable biomarkers to predict which patients will benefit clinically from ICIs therapy is critical. Depression, a common form of chronic psychological stress, has emerged as a regulator of tumor immunity and is gaining attention as a target for novel cancer treatments. To date, no studies have explored the potential of depression-related genes in predicting response to ICIs therapy.

Methods

Public datas

SUBMITTER: Zuo Q 

PROVIDER: S-EPMC12318748 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature